Genprex, Inc., an Austin, Texas-based biopharmaceutical company focused on the development of innovative immunogene therapy treatments, completed an additional funding of undisclosed amount.
The round was led by Inception Capital Management, a venture capital firm specializing in emerging technology companies.
Led by CEO Rodney Varner, newly appointed Chief Operating Officer Julien Pham, MD, MPH, and Chief Financial Officer Ryan Confer, Genprex focuses on developing new immunogene therapies. Its lead product – Oncoprex – is currently in a Phase II clinical trial for the treatment of stage IV non-small cell lung cancer in combination with Tarceva® (erlotinib) at an academic cancer research center in Houston, Texas.
The company was founded in 2009.